Artiva Biotherapeutics (ARTV) Common Equity (2023 - 2025)
Historic Common Equity for Artiva Biotherapeutics (ARTV) over the last 3 years, with Q3 2025 value amounting to $129.2 million.
- Artiva Biotherapeutics' Common Equity fell 3570.82% to $129.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $129.2 million, marking a year-over-year decrease of 3570.82%. This contributed to the annual value of $186.6 million for FY2024, which is 21519.98% up from last year.
- Per Artiva Biotherapeutics' latest filing, its Common Equity stood at $129.2 million for Q3 2025, which was down 3570.82% from $149.0 million recorded in Q2 2025.
- Artiva Biotherapeutics' 5-year Common Equity high stood at $201.0 million for Q3 2024, and its period low was -$191.1 million during Q2 2024.
- In the last 3 years, Artiva Biotherapeutics' Common Equity had a median value of -$11.1 million in 2023 and averaged -$880900.0.
- In the last 5 years, Artiva Biotherapeutics' Common Equity soared by 23271.09% in 2024 and then plummeted by 3570.82% in 2025.
- Quarter analysis of 3 years shows Artiva Biotherapeutics' Common Equity stood at -$162.0 million in 2023, then skyrocketed by 215.2% to $186.6 million in 2024, then plummeted by 30.76% to $129.2 million in 2025.
- Its Common Equity was $129.2 million in Q3 2025, compared to $149.0 million in Q2 2025 and $168.8 million in Q1 2025.